Adverse effects of prolactin in rodents and humans: breast and prostate cancer.
about
Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions.A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: the impact of duration of use, cumulative dose and latency.The risk for breast cancer is not evidently increased in women with hyperprolactinemia.Cancer and schizophrenia: is there a paradox?Effects of metoclopramide on mRNA levels of steroid 5α-reductase isozymes in prostate of adult rats.The evolution of hyperprolactinaemia as an entity in psychiatric patients.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder.Role of sex hormones in the modulation of cholangiocyte function.Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck.Adapter protein SH2B1beta binds filamin A to regulate prolactin-dependent cytoskeletal reorganization and cell motility.Tyrosyl phosphorylated PAK1 regulates breast cancer cell motility in response to prolactin through filamin AA Novel Nectin-mediated Cell Adhesion Apparatus That Is Implicated in Prolactin Receptor Signaling for Mammary Gland Development.Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder.Successful treatment of refractory diamond-blackfan anemia using metoclopramide and prednisolone.Hyperprolactinaemia during treatment with paliperidone.Schizophrenia and cancer: in 2010 do we understand the connection?Preclinical risk assessment of drug-induced hypo- and hyperprolactinemia.Hypothesis: prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific.Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.Triple negative breast cancer in a male-to-female transsexual.Use of asenapine in clinical practice for the management of bipolar mania.Derivation of an oral reference dose (RfD) for the nonphthalate alternative plasticizer 1,2-cyclohexane dicarboxylic acid, di-isononyl ester (DINCH).European Union's strategy on endocrine disrupting chemicals and the current position of Slovenia.Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons.Lactational exposure to atypical antipsychotic drugs disrupts the pituitary-testicular axis in mice neonates during post-natal development.Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics.Prolactin promotes hepatocellular carcinoma through Janus kinase 2.
P2860
Q33632082-2C4B6068-F6F6-4927-B420-2C5E8A6F05AEQ33777598-20F3A88E-38FE-4993-9B67-F2FDFBDA875CQ34031912-97CEF9D6-FDFB-4980-9A54-BE5EA1794D72Q34183508-B698920A-AA77-409B-BF77-D3E53833D06DQ34340725-D1FECF65-50D5-40AE-A618-6B3CBBF35A26Q34591930-D549C9B7-DB8C-4727-A22B-81305E62BDECQ34623350-D4610AF5-C67E-40BD-A61F-8A2CAC115460Q34649187-8C53D829-72CD-437F-AAA1-00111B3756AEQ34992322-3C52DDE2-74F6-461F-AC16-0638D0F8183FQ35006785-88952A7C-52BD-4B5E-94A9-56658C936E53Q35073608-A723A824-4A9D-48EC-893A-04E8522F47F6Q36660604-81929306-5F3C-4F9F-94B1-FEB9F1285607Q36674694-95A72932-61AB-46D3-929E-900ADF51F574Q37162812-84939D6A-54DC-45A5-8531-6569D03D3232Q37703146-C7AB7689-4DE8-4329-BA6B-940D994F1275Q37739435-CB6D2CC3-7011-49F2-8C1D-DB616983C674Q37822484-DA036680-5E82-4EF8-9E21-2A1F79998306Q37925692-2504944F-54A4-4037-82A4-54C518DC5F4FQ37957807-F8D09757-9E66-45EC-8CDA-63437B290530Q37999566-6D55A114-68E0-485A-BB36-C30449B13522Q38080937-1C02D2C1-77C7-49C9-9BC0-777B14215353Q38093728-30940824-7C4D-4C8C-841F-2C4E43AF1BB0Q38195852-E7C3F5F1-53E0-4B86-9776-FADB2F80D291Q38872937-3F664B88-BF0C-4E34-BB3F-40CC0169C512Q39453462-D70DA141-9187-4D62-AA24-0C8ABE8A8DBFQ43191868-3204C0F3-F1E1-4747-82F0-704C832EC668Q46110645-AD4A6332-7C00-4D96-A398-EADB5E2E4EC3Q46597827-4157E16B-A099-47BC-B246-F367AE6EE01EQ54525376-DA408C2B-FD02-4707-876C-297F5A42922C
P2860
Adverse effects of prolactin in rodents and humans: breast and prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adverse effects of prolactin in rodents and humans: breast and prostate cancer.
@en
Adverse effects of prolactin in rodents and humans: breast and prostate cancer.
@nl
type
label
Adverse effects of prolactin in rodents and humans: breast and prostate cancer.
@en
Adverse effects of prolactin in rodents and humans: breast and prostate cancer.
@nl
prefLabel
Adverse effects of prolactin in rodents and humans: breast and prostate cancer.
@en
Adverse effects of prolactin in rodents and humans: breast and prostate cancer.
@nl
P2093
P2860
P356
P1476
Adverse effects of prolactin in rodents and humans: breast and prostate cancer.
@en
P2093
Christopher J Springall
David J Everett
Philip W Harvey
P2860
P356
10.1177/0269881107082624
P407
P433
P577
2008-03-01T00:00:00Z